|
Sign In to gain access to subscriptions and/or personal tools.
|
The effects and after-effects of interferon alpha on human performance, mood and physiological functions
A.P. Smith
Health Psychology Research Unit, School of Psychology, University of Wales College of Cardiff, PO Box 901, Cardiff CF1 3YG
D.A.J. Tyrrell
MRC Common Cold Unit, Harvard Hospital, Coombe Road, Salisbury, Wiltshire SP2 8BW
K.B. Coyle
MRC Applied Psychology Unit, 15 Chaucer Road, Cambridge CB2 2EF, UK
P.G. Higgins
MRC Common Cold Unit, Harvard Hospital, Coombe Road, Salisbury, Wiltshire SP2 8BW
The effects of three doses of interferon alpha (IFN , 1.5 Mu, 0.5 Mu and 0.1 Mu) on performance, mood and physiological function were examined in a double-blind placebo controlled trial. The subjects given an injection of 1.5 Mu showed symptoms which closely resembled those seen in influenza, although most of the symptoms had gone by the next day. All of the doses of IFN reduced subjective ratings of alertness, but again this effect was only apparent on the day of challenge. Subjects given the 1.5 Mu injection were slower on two of the performance tasks (a simple reaction time task and a pegboard task) both on the day of challenge and the following day. None of the other tasks in the battery was impaired by any of the doses of IFN, either on the day of challenge or the following day. These results suggest that IFN has selective effects on performance, and it is possible that IFN-induced changes in CNS function provide a mechanism through which viral infections influence behaviour.
Journal of Psychopharmacology, Vol. 5, No. 3,
243-250 (1991)
DOI: 10.1177/026988119100500311

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Smith, W. Sturgess, N. Richi, C. Brice, C. Collisonl, J. Bailey, S. Wilson, and D. J. Nutt
The effects of idazoxan on reaction times, eye movements and the mood of healthy volunteers and patients with upper respiratory tract illnesses
J Psychopharmacol,
March 1, 1999;
13(2):
148 - 151.
[Abstract]
[PDF]
|
 |
|
|
|